Literature DB >> 4288576

Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone.

D J Sutherland, J L Ruse, J C Laidlaw.   

Abstract

A father and son are described with a condition characterized by benign hypertension, potassium deficiency, increased aldosterone secretion rate (ASR), raised plasma volume and suppressed plasma renin activity (PRA). There were intermittent elevations of urine 17-ketosteroids and 17-hydroxycorticoids (17-OHCS) but no increase in urine THS, normal circadian rhythm of plasma 17-OHCS, and normal urine 17-OHCS response to dexamethasone and intravenous ACTH. Plasma ACTH and corticosterone secretion were not elevated. Pregnanetriol excretion was normal but urine pregnanediol was increased. At operation on the father no adrenal tumour was found; the excised left adrenal weighed 7 g. and showed nodular cortical hyperplasia; juxtaglomerular cells showed only occasional granules. Following operation hypertension persisted and ASR was half the preoperative value. All abnormalities in father and son were relieved by dexamethasone (DM) 2 mg. daily. The condition recurred following cessation of DM but was relieved by a second course of treatment. No such response to DM was seen in a normal subject or in a patient with Conn's syndrome. For a number of reasons it is suggested that patients with hypertension, increased ASR and low PRA be given a trial of dexamethasone treatment before undergoing adrenal surgery.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 4288576      PMCID: PMC1935810     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  23 in total

Review 1.  CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.

Authors:  J W CONN; R F KNOPF; R M NESBIT
Journal:  Am J Surg       Date:  1964-01       Impact factor: 2.565

2.  SIMULTANEOUS MEASUREMENT OF SECRETORY RATES OF ALDOSTERONE AND 18-HYDROXYCORTICOSTERONE.

Authors:  S ULICK; K K VETTER
Journal:  J Clin Endocrinol Metab       Date:  1965-08       Impact factor: 5.958

3.  ALDOSTERONE SECRETION RATE IN CONGENITAL ADRENAL HYPERPLASIA. A DISCUSSION OF THE THEORIES ON THE PATHOGENESIS OF THE SALT-LOSING FORM OF THE SYNDROME.

Authors:  A KOWARSKI; J W FINKELSTEIN; J S SPAULDING; G H HOLMAN; C J MIGEON
Journal:  J Clin Invest       Date:  1965-09       Impact factor: 14.808

4.  NORMAL AND ALTERED FUNCTION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN MAN: APPLICATIONS IN CLINICAL AND RESEARCH MEDICINE.

Authors:  J W CONN; D R ROVNER; E L COHEN
Journal:  Ann Intern Med       Date:  1965-08       Impact factor: 25.391

5.  A test of pituitary reserve utilizing intravenous SU-4885, with a new method for extraction of 11-desoxvcorticosteroids.

Authors:  W J HENKE; R P DOE; M E JACOBSON
Journal:  J Clin Endocrinol Metab       Date:  1960-11       Impact factor: 5.958

6.  Studies on adrenocortical function in obesity.

Authors:  P SZENAS; C J PATTEE
Journal:  J Clin Endocrinol Metab       Date:  1959-03       Impact factor: 5.958

7.  [A method for the clinical routine determination of urinary estrogens].

Authors:  G ITTRICH
Journal:  Zentralbl Gynakol       Date:  1960-03-12

8.  HYPERTENSION DUE TO RENAL ARTERY OCCLUSION SIMULATING PRIMARY ALDOSTERONISM.

Authors:  J C LAIDLAW; E R YENDT; C E BIRD; A G GORNALL
Journal:  Can Med Assoc J       Date:  1964-01-25       Impact factor: 8.262

9.  Modification of the Reddy-Jenkins-Thorn method for the estimation of 17-hydroxycorticoids in urine.

Authors:  W J REDDY
Journal:  Metabolism       Date:  1954-11       Impact factor: 8.694

10.  The true endogenous creatinine clearance.

Authors:  H N HAUGEN; E M BLEGEN
Journal:  Scand J Clin Lab Invest       Date:  1953       Impact factor: 1.713

View more
  72 in total

Review 1.  Primary aldosteronism.

Authors:  R D Gordon
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 2.  Primary aldosteronism in 2011: Towards a better understanding of causation and consequences.

Authors:  Michael Stowasser
Journal:  Nat Rev Endocrinol       Date:  2011-12-13       Impact factor: 43.330

3.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 4.  Molecular and clinical investigations in patients with low-renin hypertension.

Authors:  Isla S Mackenzie; Morris J Brown
Journal:  Clin Exp Nephrol       Date:  2008-08-15       Impact factor: 2.801

5.  Variation of phenotype in patients with glucocorticoid remediable aldosteronism.

Authors:  L J Gates; A A MacConnachie; R P Lifton; N E Haites; N Benjamin
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

Review 6.  Genetics of hypertension. Therapeutic implications.

Authors:  S O'Byrne; M Caulfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

7.  Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree.

Authors:  L Pascoe; X Jeunemaitre; M C Lebrethon; K M Curnow; C E Gomez-Sanchez; J M Gasc; J M Saez; P Corvol
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 8.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

Review 9.  Primary Aldosteronism: Practical Approach to Diagnosis and Management.

Authors:  James Brian Byrd; Adina F Turcu; Richard J Auchus
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 10.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.